TRiP research group


Dr. Juliane Müller, MD
Senior Psychiatrist
Dept. of Psychiatry, Psychotherapy and Psychosomatics
Goethe-University Frankfurt am Main

Research interests/ Focus of work:
Early phase clinical trials, Innovative treatments for psychiatric disorders,
Neurobiology of emotion regulation

Academic Education:
2001–2004 Study of Medicine, University of Regensburg
2004–2008 Study of Medicine, Ludwig-Maximillians-University Munich
2008 Medical license
Doctoral thesis:
2015 "Tryptophanhydroxylase isoenzymes 1 and 2 in the human brain: regional distribution and potential alterations in psychiatric disorders.", Ludwig-Maximillians-University Munich
Board certificates:
2016 Psychiatry and Psychotherapy
Professional experience:
2008–2010 Resident in Psychiatry and Psychotherapy, Dept. of Psychiatry and Psychotherapy, Goethe University Frankfurt am Main (Director: Prof. Dr. H. Hampel)
2010–2016 Resident in Psychiatry and Psychotherapy, Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health (Director: Prof. Dr. A. Meyer-Lindenberg)
thereof 2012-2013 Resident in Neurology, Dept. of Neurology, University Hospital Heidelberg (Director: Prof. Dr. W. Wick)
2016-2018 Specialist in Psychiatry and Psychotherapy and Research Fellow, Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health
since 2018 Psychiatric Staff Specialist, Dept. of Psychiatry, Psychotherapy and Psychosomatics, Goethe-University Frankfurt am Main (Director: Prof. Dr. A. Reif)

  • F. M. Leweke, C. Rohleder, J. K. Mueller, D. Hirjak, A. Meyer-Lindenberg (2018) [Enhancing recovery in early schizophrenia by controlled add-on of cannabidiol to an individualized antipsychotic treatment – a randomized clinical trial.] Nervenheilkunde, in press
  • B. Lange, J. K. Mueller, F. M. Leweke, J. M. Bumb (2017) How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review. Expert Opin Pharmacother 18:351-362
  • A. R. Reuter*, J. M. Bumb*, J. K. Mueller*, C. Rohleder, F. Pahlisch, F. Hanke, E. Arens, F. M. Leweke, D. Koethe, E. Schwarz (2017) Association of anandamide with altered binocular depth inversion illusion in schizophrenia. World J Biol Psychiatry 18:483-488
  • J. K. Mueller, C. Rohleder, F. M. Leweke (2016) What is the promise of nicotinergic compounds in schizophrenia treatment? Future Med Chem 8:2009-2012
  • F. M. Leweke, J. K. Mueller, B. Lange, C. Rohleder (2016) Therapeutic potential of cannabinoids in psychosis. Biol Psychiatry 79:604-612
  • J. M. Bumb, F. Enning, J. K. Mueller, T. van der List, C. Rohleder, P. Findeisen, I. Noelte, E. Schwarz, F. M. Leweke (2016) Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. Comp Psychiatry 68:34-39
  • E. G. Severance, K. L. Gressitt, A. Alaedini, C. Rohleder, F. Enning, J. M. Bumb, J. K. Mueller, E. Schwarz, R. H. Yolken, F. M. Leweke (2015) IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. Brain Behav Immun 44:148-58.
  • C. Schaefer*, F. Enning*, J. K. Mueller*, J. M. Bumb*, C. Rohleder, T. M. Odorfer, J. Klosterkotter, M. Hellmich, D. Koethe, C. Schmahl, M. Bohus, F. M. Leweke (2014) Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. Eur Arch Psychiatry Clin Neurosci 264:459-463.
  • P. Zill, A. Buttner, W. Eisenmenger, J. Muller, H. J. Moller, B. Bondy (2009) Predominant expression of tryptophan hydroxylase 1 mRNA in the pituitary: a postmortem study in human brain. Neuroscience 159:1274-1282.